Cytosorbents Corporation develops blood purification technologies for life-threatening conditions in intensive care and cardiac surgery. Its lead product, CytoSorb®, is approved in the European Union, distributed internationally, and used for cytokine adsorption and CE-marked applications that include bilirubin, myoglobin, ticagrelor, and rivaroxaban removal; in the United States it has FDA Emergency Use Authorization for adult critically ill COVID-19 patients with respiratory failure and is not otherwise approved or cleared.
Company updates commonly address quarterly and annual results, gross margin and balance-sheet actions, product launches such as HotSwap™, distribution partnerships, clinical evidence for CytoSorb therapy, and regulatory work around the investigational DrugSorb®-ATR antithrombotic removal system. The product portfolio also includes ECOS-300CY®, CytoSorb-XL™, HemoDefend-RBC™, HemoDefend-BGA™, VetResQ®, K+ontrol™, ContrastSorb, PuriFi®, and related blood purification technologies.
CytoSorbents (CTSO) announced upcoming CytoSorb data presentations at international cardiac surgery and critical care conferences in October 2026. The EACTS Annual Meeting runs October 7–10 in Barcelona, Spain; the ESICM Annual Congress runs October 10–14 in Lisbon, Portugal.
Cardiac surgery presentations cover blood-thinner removal, postoperative vasoplegia and heart transplantation. Critical care presentations include liver support, hyperinflammation during extracorporeal membrane oxygenation, a form of external life support, and sepsis. Several presentations draw on the international, prospective COSMOS Registry, including an analysis of its first 200 patients with sepsis and septic shock.
CytoSorbents (CTSO) has regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share. On September 22, 2026, the company received notice from Nasdaq's Listing Qualifications Department that its common stock met Nasdaq Listing Rule 5550(a)(2) after maintaining a closing bid price of at least $1.00 for 10 consecutive trading days ending September 21, 2026, and Nasdaq considers the matter closed.
The company is now focused on regaining full compliance with all Nasdaq Capital Market listing requirements, including the minimum Market Value of Listed Securities under Rule 5550(b)(2), or alternative criteria, before the December 28, 2026 compliance deadline. Management also highlights ongoing priorities such as driving CytoSorb sales, targeting operating cash flow breakeven in the second half of this year, advancing the investigational DrugSorb-ATR toward FDA approval, and developing additional blood purification assets.
CytoSorbents (CTSO) will participate in the H.C. Wainwright 28th Annual Global Investment Conference in New York City from September 14–16, 2026. On Monday, September 14, 2026, at 11:30 a.m. EDT, CEO Dr. Phillip Chan and CFO Peter Mariani will join Sean Lee, Vice President, Equity Research at H.C. Wainwright, for a fireside chat at the Lotte New York Palace Hotel.
The session will be webcast at a provided link, with a replay available for up to 90 days. CytoSorbents develops blood purification technologies, including its lead product CytoSorb, which is approved in the European Union and distributed in over 70 countries, and the investigational DrugSorb-ATR system under development in the U.S. and Canada.
CytoSorbents (CTSO) will present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference in New York City on September 9-10, 2026. CEO Dr. Phillip Chan and CFO Peter Mariani will deliver an investor presentation and hold 1-on-1 meetings with investors.
The investor presentation is scheduled for Thursday, September 10, 2026 at 2:50 p.m. EST at The Westin New York Grand Central, 212 E 42nd St, New York, NY. The conference features company presentations, investor meetings, fireside chats, and capital markets panels focused on growth and life sciences companies.
CytoSorbents (CTSO) will implement a one-for-twenty (1:20) reverse stock split of its common stock, effective September 8, 2026, to support compliance with Nasdaq’s $1.00 minimum bid price requirement.
At the effective time, every 20 issued and outstanding common shares will be automatically converted into 1 share, and the stock will begin trading on a split-adjusted basis at market open on September 8, 2026, under the existing symbol CTSO with a new CUSIP (23283X305). The split will proportionately reduce the approximately 63,022,020 shares currently outstanding to an expected 3,151,101 shares, before rounding. No fractional shares will be issued; any fractional entitlement will be rounded up to the nearest whole share. The total number of authorized shares will remain unchanged, and outstanding options and warrants plus their exercise prices will be adjusted proportionately. Shareholders holding in book-entry or through brokers are not expected to take any action.
CytoSorbents (CTSO) reported new real-world, patient-level matched data showing that intraoperative CytoSorb use during urgent CABG surgery in ticagrelor-treated patients was associated with a 37% relative reduction in severe BARC-4 bleeding (21.8% vs 34.5%; p=0.002).
The analysis compared 198 CytoSorb-treated patients from the STAR-T Registry with 389 matched controls from a prior meta-analysis, found an NNT of 8 to prevent one severe bleeding event, and showed significant reductions in 24-hour chest tube drainage (p=0.039) and red blood cell transfusions (p=0.003), with no serious device-related adverse events reported. The company expects these data to form a core component of a strengthened U.S. FDA De Novo submission for DrugSorb-ATR for Brilinta patients, increasing the treated patient dataset to roughly 250. Two recent FDA Pre-Submission meetings provided constructive feedback on mechanistic and clinical evidence for separate De Novo pathways for ticagrelor and DOAC removal, with a new Brilinta-focused De Novo filing planned for early 2027 under Breakthrough Device designation.
CytoSorbents (NASDAQ: CTSO) reported second quarter 2026 revenue of $9.6 million, flat year over year, with gross margin improving to 73% from 71% a year ago and 69% in Q1 2026. Operating loss narrowed 27% to $2.6 million. Net loss was $4.4 million, or $0.07 per share, versus net income of $1.9 million, or $0.03 per share, in Q2 2025, mainly due to non-cash foreign currency translation effects. Adjusted net loss improved 22% to $2.8 million, while adjusted EBITDA loss improved 38% to $1.6 million.
Total cash, cash equivalents, and restricted cash were $5.9 million at June 30, 2026, with quarterly cash burn reduced to $0.4 million, including $0.2 million of restructuring payments. The company highlighted four value drivers: achieving operating cash flow breakeven, returning the CytoSorb business to profitable growth, securing FDA approval for DrugSorb-ATR to open the U.S. market, and unlocking strategic options for HemoDefend-BGA following recent FDA feedback and prior $16 million in non-dilutive funding.
CytoSorbents (NASDAQ: CTSO) will report its second quarter 2026 financial results and recent business highlights after market close on Thursday, August 6, 2026. Management will host a live conference call, webcast, and Q&A at 4:30 PM ET the same day.
The live webcast will be accessible at https://app.webinar.net/v62381bx4na, with an archived recording available later in the Investor Relations section of the company’s website. CytoSorbents develops blood purification technologies for critical care and cardiac surgery, including the CytoSorb and investigational DrugSorb-ATR systems.
CytoSorbents (NASDAQ: CTSO) reported Q1 2026 revenue of $8.9 million, up 2% year-over-year, with a 69% gross margin. Operating loss improved to $3.0 million, while net loss increased to $5.1 million, mainly from non-cash foreign currency effects. Cash stood at $6.4 million, with approximately $1.1 million quarterly cash burn excluding restructuring.
The company cited 13% growth in direct sales territories outside Germany, benefits from a 10% prior headcount reduction, and continued progress toward operating cash flow breakeven in 2H 2026. It is preparing a new De Novo submission for DrugSorb-ATR for Brilinta, targeting late 2026 or early 2027, and assessing a parallel De Novo path for DOAC removal. New clinical and health-economic data support safety, bleeding reduction in CABG subpopulations, and cost-effectiveness in septic shock.
CytoSorbents (NASDAQ: CTSO) will report first quarter 2026 financial results and recent business highlights after market close on Wednesday, May 13, 2026. Management will host a live conference call, webcast presentation, and Q&A starting at 4:30 PM ET the same day.
Investors are advised to dial in ~10 minutes early. A recorded archive will be available on the company's Investor Relations website.